Growth Metrics

TriSalus Life Sciences (TLSI) Net Cash Flow (2021 - 2026)

TriSalus Life Sciences has reported Net Cash Flow over the past 5 years, most recently at $35.8 million for Q1 2026.

  • For Q1 2026, Net Cash Flow rose 699.2% year-over-year to $35.8 million; the TTM value through Mar 2026 reached $43.2 million, up 378.44%, while the annual FY2025 figure was $11.9 million, 466.36% up from the prior year.
  • Net Cash Flow for Q1 2026 was $35.8 million at TriSalus Life Sciences, up from -$2.2 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $35.8 million in Q1 2026 and troughed at -$17.8 million in Q3 2022.
  • A 5-year average of $1.5 million and a median of -$2.6 million in 2023 define the central range for Net Cash Flow.
  • Biggest five-year swings in Net Cash Flow: crashed 15785.95% in 2023 and later skyrocketed 699.2% in 2026.
  • Year by year, Net Cash Flow stood at -$2.7 million in 2022, then crashed by 255.5% to -$9.5 million in 2023, then skyrocketed by 70.93% to -$2.8 million in 2024, then grew by 18.64% to -$2.2 million in 2025, then surged by 1690.93% to $35.8 million in 2026.
  • Business Quant data shows Net Cash Flow for TLSI at $35.8 million in Q1 2026, -$2.2 million in Q4 2025, and -$3.8 million in Q3 2025.